About Us

Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.

Our Team


Josh Riggs

President & Chief Executive Officer

Josh joined Oncocyte Corporation in August 2020 and was appointed Interim Chief Executive Officer in December 2022, after serving as Senior Director Business Development and General Manager, Transplant. Josh is an experienced business leader and was previously the founder and principal of Intelliger Consulting, an organization devoted to consumer driven healthcare, and a principal at Bethesda Group, LLC, a boutique consulting group focused on helping small and mid-stage diagnostic companies and investment groups move emerging diagnostic content and platforms to market.

Anish John

Chief Financial Officer

Anish joined Oncocyte Corporation in September 2021 and was named Chief Financial Officer in August 2022, following a two-month period as Senior Vice President, Finance and interim Chief Financial Officer. He previously served as our Vice President of Operations and Finance, Transplant Business Unit. Anish brings over 15 years of financial and operations leadership experience in companies ranging from startup through Fortune 500 heavily matrixed global organizations in Biotech, Pharma, High Technology, Diagnostics, and Clinical Lab Services.

Anish harnesses his mix of operations and financial insight to strategically optimize investment allocation to fuel predictable and profitable company growth. Known as a collaborative and trusted advisor, Anish guides senior leadership through tradeoffs and portfolio decision-making. His passion for effective financial thought leadership is manifested in his belief that finding creative ways to invest in innovation is the key to building enterprise and shareholder value.

Before he joined Oncocyte, Anish earned a reputation for building high performance finance and accounting teams that function as business partners to enable company innovation. Most recently, as Senior Director of Financial Planning and Analysis (FP&A) at Foundation Medicine, Inc. (wholly owned subsidiary of Roche Holding, AG), Anish evolved the financial planning and forecasting process that aligned strategy, business functions, and the product portfolio. He optimized forecast investment levels to drive double-digit 2020 revenue growth and profit expansion. He also led the development of robust scenario-driven forecasting models and FP&A processes to support insightful, agile decision making in periods of market uncertainty, including COVID-19 impact on trials and lab services.

Anish enabled business models to balance risks and opportunities across the portfolio of four core Diagnostics franchises while Senior Director of Finance, Americas Diagnostics, at PerkinElmer, Inc., a leading Fortune 500 diversified life science company (NYSE: PKI). Through his team’s efforts, the company’s Americas Diagnostics Division consistently grew annual portfolio revenues in the high single digits organically and delivered on plan revenues while expanding gross margins and gross profit over 150 basis points.

Anish holds a Master of Business Administration from Babson College in Wellesley and a Bachelor of Business Administration in Finance from the University of Massachusetts Amherst.

Prof. Dr. Ekkehard Schütz, MD, PhD, FAACC

Chief Science Officer

Ekkehard (Ekke) joined Oncocyte in April 2021 through the acquisition of Chronix Biomedical. Ekke serves as the managing director of Chronix Biomedical GmbH, wholly owned by Oncocyte and CMO for Europe. As an adjunct professor, he teaches molecular genetics and diagnostics at the Georg-August-University.

Ekke received his training in laboratory medicine (chemical pathology) at the Dept. of Clinical Chemistry in the hospital of the Georg-August-University of Göttingen, where he worked from 1989 to 2001 under Prof. Dr. Michael Oellerich, a world expert in therapeutic drug monitoring and transplantation surveillance. He joined Chronix Biomedical Inc. (San Jose, CA) in 2001. He established its German subsidiary in 2002 as the R&D site of the company. Chronix became an industry leader in cell-free DNA (cf-DNA) diagnostics, which resulted in numerous scientific publications and a broad patent portfolio in cf-DNA diagnostics in cancer and transplantation with ten different patent families and multiple issued IP in the US and Europe of which Ekke is the inventor.

In 2014 was elected as a fellow of the National Academy for Clinical Biochemistry, which became the Academy of the American Association for Clinical Chemistry (FAACC). Besides his broad experience in patenting, Ekke has published over 170 peer-reviewed publications and book chapters, over 100 published congress abstracts, has received several international scientific awards, and serves as a reviewer for numerous international scientific journals, including PNAS, Clin Chem, Clin Biochem and NAR.

Yuh-Min (Johnson) Chiang, PhD

Chief Technology Officer

Johnson joined Oncocyte Corporate in September 2021. Prior to joining Oncocyte, Johnson holds the Chief Technology Officer in Alveo Technologies, an IVD company focusing on development of cutting edge molecular diagnostic tests for Over The Counter (OTC) and Point-Of-Care (POC) applications. Johnson led the teams to develop the COVID-19 be.well Test for a successful US clinical trial and obtained the CE mark and UK approval.

At Alveo, Johnson also participated in fundraising of about $50MM in 4 years, including winning the XPrize Grand Award for Rapid Covid Testing Competition. Before Alveo Technologies, Johnson was the Head of Systems Integration & Molecular Biology at Foundation Medicine, Inc. and held senior management positions at Life Technologies and Thermo Fisher Scientific where he led systems design, integration, verification and validation for qPCR and next-generation sequencing platforms, including Oncomine Dx Target Test as the very first NGS-based CDx test approved by FDA. Johnson also worked at Cepheid where he oversaw a few key product developments from the concept to commercialization under FDA regulation. He has extensive experience and successful track records in product development (device, instrument, SW, and assays) as well as design control for 510k and PMA applications. Johnson also owns several patents and published numerous biotechnology papers.

Johnson holds a Ph.D. degree focused on BioMEMS (Micro Electro-Mechanical Systems) from University of California, Irvine. He received his Master in Engineering from The Ohio State University and Bachelor of Applied Chemistry from National Chiao Tung University, Taiwan.

Photo of pipette dropping liquid in test tubes

Contact Us